Use this button to switch between dark and light mode.

The TRIPS Patent Waiver: Much Ado About Nothing or the Thin Edge of the Wedge?

June 22, 2021 (1 min read)

Check out this analysis of the U.S. government’s recent controversial decision to engage in discussions with other World Trade Organization member states on a proposal to waive patent rights for COVID-19 vaccines.

READ NOW »

Related Content

  • FDA Regulation of Pharmaceuticals
    Learn the requirements for FDA drug approval and the key activities manufacturers must complete prior to marketing a new drug product in the United States.
  • Hatch-Waxman Act Fundamentals
    Brush up on the approval process for prescription drugs under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Act.
  • Hatch-Waxman Safe Harbor Checklist
    Refer to this checklist to review which acts in the drug development process fall under the safe harbor provision of the Hatch-Waxman Act.

 

Practical Guidance Updates

Featuring the latest updates from your Practical Guidance account.   


Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+